Loading cancer entity…
Loading cancer entity…
Clinical trials
42 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01799538 | Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis | recruiting | Phase 1 / Phase 2 | 100 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Aug 31, 2026 | clinicaltrials |
| NCT03304678 | Discovery of Sirolimus Sensitive Biomarkers in Blood | completed | Phase 2 | 33 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Feb 18, 2026 | clinicaltrials |
| NCT05467397 | Feasibility of [11C]Acetate-PET in LAM and TSC | active not recruiting | Phase 1 / Phase 2 | 7 | Brigham and Women's HospitalOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT01353209 | Letrozole for Lymphangioleiomyomatosis(TRAIL) | completed | Phase 2 | 17 | University of CincinnatiOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT03253913 | Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial(RESULT) | completed | Phase 2 | 25 | University of CincinnatiOTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT03062943 | A Study of Nintedanib for LymphAngioleioMyomatosis (LAM)(LAM) | completed | Phase 2 | 30 | IRCCS MultimedicaOTHER | 1 | Sep 28, 2022 | clinicaltrials |
| NCT05190627 | Effect of Loratadine in Lymphangioleiomyomatosis(LORALAM) | unknown | Phase 2 | 62 | Institut d'Investigació Biomèdica de BellvitgeOTHER | 1 | Jan 27, 2022 | clinicaltrials |
| NCT02484664 | COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC(COLA) | completed | Phase 2 | 12 | Brigham and Women's HospitalOTHER | 1 | Jan 20, 2022 | clinicaltrials |
| NCT01059318 | A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis | completed | Phase 2 | 24 | Novartis PharmaceuticalsINDUSTRY | 3 | Nov 19, 2020 | clinicaltrials |
| NCT02061397 | Safety of Simvastatin in LAM and TSC(SOS) | completed | Phase 1 / Phase 2 | 10 | University of PennsylvaniaOTHER | 1 | Aug 25, 2020 | clinicaltrials |
| NCT03131999 | LAM Pilot Study With Imatinib Mesylate(LAMP-1) | completed | Phase 1 / Phase 2 | 18 | Medical University of South CarolinaOTHER | 1 | Jun 16, 2020 | clinicaltrials |
| NCT00457964 | RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM | completed | Phase 1 / Phase 2 | 36 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Sep 25, 2013 | clinicaltrials |
| NCT00005906 | Treatment With Octreotide in Patients With Lymphangioleiomyomatosis | completed | Phase 2 | 4 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Apr 30, 2010 | clinicaltrials |
| NCT00490789 | Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM(TESSTAL) | unknown | Phase 2 | 14 | Cardiff UniversityOTHER | 1 | Apr 30, 2008 | clinicaltrials |
| NCT00457808 | Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM | completed | Phase 2 | 25 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Apr 9, 2007 | clinicaltrials |
Data updated 22 days agoSource updated Aug 31, 2026source: clinicaltrials